Global Peptide CDMO Services Market Growth (Status and Outlook) 2025-2031

The global Peptide CDMO Services market size is predicted to grow from US$ 4700 million in 2025 to US$ 11160 million in 2031; it is expected to grow at a CAGR of 15.5% from 2025 to 2031.

Peptide CDMO Services refer to the specialized contract development and manufacturing services offered by third-party organizations to assist pharmaceutical companies in the production of peptide-based therapeutics. These services typically include peptide synthesis, purification, formulation, and analytical testing to ensure that the peptides meet required quality, purity, and stability standards. CDMOs in this sector provide the expertise and infrastructure needed for large-scale production, offering cost-effective solutions and faster time-to-market for peptide drugs. With the growing demand for personalized medicines and the increasing role of peptides in treating various diseases, including cancer, diabetes, and neurological disorders, peptide CDMOs play a crucial role in the development and manufacturing of peptide therapeutics.

The demand for Peptide CDMO (Contract Development and Manufacturing Organization) services is driven by the growing focus on peptide-based therapeutics in the pharmaceutical industry. Peptides are becoming increasingly important in treating a wide range of diseases, including cancer, endocrine disorders, neurological conditions, and autoimmune diseases, due to their ability to offer high specificity, targeted delivery, and fewer side effects compared to traditional small molecules. As the complexity of peptide drugs increases, pharmaceutical companies are increasingly outsourcing the development and manufacturing of these drugs to Peptide CDMOs, which offer specialized expertise, advanced technologies, and scalable production capabilities. This trend is amplified by the rise in biopharmaceutical outsourcing, with companies looking to reduce time-to-market and costs while focusing on their core competencies in research and development.Despite the growing demand for peptide CDMO services, the market faces challenges related to the complexity and cost of peptide synthesis and manufacturing. Peptides often require specialized technologies for synthesis, purification, and formulation, which can make the process both expensive and time-consuming. The production of high-quality peptides at large scale involves significant technical hurdles, such as ensuring purity, stability, and yield, which increases operational costs for CDMOs. Additionally, regulatory hurdles pose a challenge, as peptides often require more stringent oversight compared to traditional drugs. This includes the need for comprehensive documentation, clinical trials, and compliance with GMP (Good Manufacturing Practices). These factors may limit the ability of some smaller CDMOs to compete effectively, making it difficult for them to meet the increasing demand while ensuring high-quality standards..

LPI (LP Information)' newest research report, the “Peptide CDMO Services Industry Forecast” looks at past sales and reviews total world Peptide CDMO Services sales in 2024, providing a comprehensive analysis by region and market sector of projected Peptide CDMO Services sales for 2025 through 2031. With Peptide CDMO Services sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Peptide CDMO Services industry.

This Insight Report provides a comprehensive analysis of the global Peptide CDMO Services landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Peptide CDMO Services portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Peptide CDMO Services market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Peptide CDMO Services and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Peptide CDMO Services.

This report presents a comprehensive overview, market shares, and growth opportunities of Peptide CDMO Services market by product type, application, key players and key regions and countries.

Segmentation by Type:
APIs and Intermediates
FDF

Segmentation by Application:
Commercial
Academic Research
Other

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Bachem
PolyPeptide
CordenPharma
AmbioPharm
USV Peptides
Thermofischer
Bio Basic
JPT
Genscript
Xinbang Pharma
ScinoPharm
SN Biopharm
CBL
Piramal Pharma
CPC Scientific

Please note: The report will take approximately 2 business days to prepare and deliver.